Patents expiring in 2039

US 10519240

Anti-FGFR1c antibody-FGF21 fusion proteins

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10519222

Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10519175

Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

COMPASS Pathways Limited · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10519186

Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

Atea Pharmaceuticals, Inc. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10519224

Treating headache comprising administering an antibody to calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

CA 3103212

FORMULATIONS COMPRENANT DES INHIBITEURS DE LA DOPAMINE-S-HYDROXYLASE ET LEURS PROCEDES DE PREPARATION

BIAL PORTELA & CA SA [PT] · Granted Thu Jan 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Dec 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)